Drugs / BTX-A51
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06414434 | Sep 2024 → Jan 2027 expected | CIC-rearranged sarcoma, myxoid liposarcoma | Michael Wagner, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04872166 | Jun 2021 → May 2026 overdue | breast cancer | Edgewood Oncology Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04243785 | Jan 2020 → Mar 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | Edgewood Oncology Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-05-29 | Biotheryx, Inc. | Regulatory BioTheryX Announces FDA Approval of IND Application to Initiate Phase 1 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia biotheryx.com ↗
today announced that the U.S. Food and Drug Administration (“FDA”) has cleared BioTheryX’s investigational new drug application (“IND”) for BTX-A51 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-05-29 | Biotheryx, Inc. | BioTheryX Announces FDA Approval of IND Application to Initiate Phase 1 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia biotheryx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTX A51 | “BACKGROUND: BTX A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by...” PMID 40665325 ↗ Jul 2025 |
| Action | Inhibit | “inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9” PMID 40665325 ↗ Jul 2025 |
| Modality | Small molecule | “BTX A51, a first-in-class oral small molecule inhibitor” PMID 40665325 ↗ Jul 2025 |
| Route | Oral | “Orally administered capsules” NCT04243785 ↗ |